ACA Benchmark Premiums Set to Rise 13% in 2027 as Drug Costs Climb

Finalized benchmark silver premiums under the Affordable Care Act (ACA) will increase by an average of 13% in 2027—marking a second consecutive year of double-digit hikes after average monthly benchmark premiums jumped from $497 in 2025 to $625 in 2026 following the expiration of enhanced premium tax credits at the end of 2025, according to a KFF analysis reported by ABC7 News journalist Mary Kekatos.

AI Medical Scribes, Medical Supply Tariffs, and $915B in Drug Spending

For employer-sponsored coverage, KFF found workers are paying nearly 10% more in premiums, while the average single-coverage deductible has risen 43% since 2015 to reach $1,886 in 2025. Policy researchers Sabrina Corlette of Georgetown University's McCourt School of Public Policy and Zack Cooper of Yale University's Health Care Affordability Lab identified three structural cost drivers:

• Ambient AI Coding & Prior Authorization Debates: Insurers including Blue Cross Blue Shield and analytics firm Trilliant Health noted that hospital adoption of ambient AI scribes to transcribe visits can turn a 20-second preventive-visit question into a higher diagnostic billing code. Meanwhile, following a November 2023 lawsuit and a 2024 Senate subcommittee report on Medicare Advantage post-acute denials, CVS and UnitedHealthcare defended their clinical practices—with UnitedHealthcare stating Medicare Advantage members see 45% lower out-of-pocket costs, a 40% lower rate of avoidable hospitalizations, and a 96% satisfaction rating—while AHIP spokesperson Chris Bond, PhRMA's Chanse Jones, and the American Hospital Association (citing 24/7 rural care access and Fortune 500 insurer consolidation) traded proposals on affordability.
• Medical Supply Tariffs: The FDA estimates 78% of active pharmaceutical ingredient manufacturers are outside the U.S. and imports account for nearly half of U.S. medical devices. A 2026 study by Georgia Tech and UC Davis found federal tariffs on imported medical supplies totaled $3.4 billion in the first 6 months of 2025, with nearly 56% passed on to providers and patients, while White House spokeswoman Allison Schuster noted 50 states, D.C., and Puerto Rico signed onto the GENEROUS Medicaid model under Most Favored Nation drug deals saving over $1 billion.
• GLP-1 Prescription Growth: The American Society of Health-System Pharmacists (ASHP) reported U.S. prescription drug spending rose 12.7% in 2025 to $915 billion (and AARP found the top 25 brand-name drugs rose 81% since market entry). Following FDA approvals since 2014—including Wegovy in 2021 and Zepbound in 2023—a July Gallup poll found 11% of U.S. adults take GLP-1 drugs for weight loss (up from 3% in 2024). A 2025 JAMA Network Open study found GLP-1 spending rose over 500% from $13.7 billion in 2018 to $71.7 billion in 2023, and at over $1,000 per month, GLP-1s represented 14% of all 2025 U.S. drug spending ($60 billion each for tirzepatide and semaglutide, versus $29 billion for third-ranked blood thinner apixaban). KFF's Matthew Rae noted 29% of covering employers call the cost impact "significant" and 27% "moderate" ahead of generic competition around 2030.

Once Upon a Farm Recalls Tractor Wheels Toddler Bars Across 45 States

In family consumer safety news, ABC7 News reported on Monday, Nov. 2, 2026 that child nutrition company Once Upon a Farm is voluntarily recalling and reformulating 3 varieties of its Tractor Wheels soft-baked toddler bars—Apple, Sweet Potato, & Spinach; Strawberry, Pumpkin, & Beet; and Banana, Pumpkin & Cauliflower—across 45 states and Puerto Rico following 3 consumer complaints and FDA reports of choking incidents and hospitalizations caused by the chewed bars forming a dry, sticky mass.